Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fibrolamellar Carcinoma: early-phase trial registry
2 of 5 indexed Fibrolamellar Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,408 of 28,963 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,408 of 28,963 conditions by registered trial count
Fibrolamellar Carcinoma: 5 US clinical trials tracked, 2 recruiting.
Fibrolamellar Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Agenus, running 1 of these trials.
Open enrollment, early-phase tilt
Fibrolamellar Carcinoma has 5 registered US clinical trials, 2 of them open to new participants right now, about 40% of the total.
- 2
- recruiting participants now
- 40%
- of trials open to enrollment
- 1
- in Phase 3-4 (later-stage)
- 1
- top sponsor: Agenus
Corpus placement: #3,408 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Fibrolamellar Carcinoma on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Fibrolamellar Carcinoma is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Fibrolamellar Carcinoma research.
Agenus accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Fibrolamellar Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 83 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Fibrolamellar Carcinoma research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
NCT05468359
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Allison O'Neill, MD
NCT04134559
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group
NCT03533582
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus
NCT03860272
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02159989
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Fibrolamellar Carcinoma right now
2 recruiting of 5 indexed (40% open).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top sponsor: Agenus (1 trial), 4 others listed. 5 shown below, recruiting first. #3,408 of 28,963 conditions by registered trial count.
Why a small condition index still matters
Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.
Frequently Asked Questions
How many clinical trials are there for Fibrolamellar Carcinoma?
PlainTrial tracks 5 US clinical trials for Fibrolamellar Carcinoma, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Fibrolamellar Carcinoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.